Safety and efficacy of continuous intravenous labetalol for blood pressure control in neurosurgical patients
Objectives Current evidence supporting the use of continuous intravenous labetalol for blood pressure (BP) control in neurosurgical patients is limited. This study aims to assess the efficacy and safety of labetalol in neurosurgical patients and identify potential contributing factors to these outco...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2023-11-01
|
| Series: | Journal of International Medical Research |
| Online Access: | https://doi.org/10.1177/03000605231212316 |
| _version_ | 1797534679386030080 |
|---|---|
| author | Raywat Noiphithak Gahn Duangprasert Sasikan Sukhor Pichayaphong Durongkaweroj Vich Yindeedej |
| author_facet | Raywat Noiphithak Gahn Duangprasert Sasikan Sukhor Pichayaphong Durongkaweroj Vich Yindeedej |
| author_sort | Raywat Noiphithak |
| collection | DOAJ |
| description | Objectives Current evidence supporting the use of continuous intravenous labetalol for blood pressure (BP) control in neurosurgical patients is limited. This study aims to assess the efficacy and safety of labetalol in neurosurgical patients and identify potential contributing factors to these outcomes. Methods We retrospectively reviewed the medical records of neurosurgical patients who received continuous labetalol infusion for BP control. Efficacy was assessed based on the time needed to achieve the target BP (systolic BP ≤ 140 mmHg or diastolic BP ≤ 90 mmHg). Safety was assessed according to adverse events that occurred during labetalol administration. Factors associated with efficacy and safety were analyzed using a logistic regression model. Results Among 79 patients enrolled in this study, 47 (59.49%) achieved the target BP within 1 hour (early response). No factors were significantly associated with an early response. Hypotension was observed in 11 patients (13.9%), and bradycardia was observed in 8 patients (10.1%). Hypotension was significantly associated with patient age and motor impairment, while bradycardia was significantly associated with diabetes mellitus. Conclusion The efficacy and safety profiles of labetalol infusion suggest this treatment as a promising option for BP control in neurosurgical patients. |
| first_indexed | 2024-03-10T11:33:51Z |
| format | Article |
| id | doaj.art-9783807094a745c1a1ae4d789606c7bd |
| institution | Directory Open Access Journal |
| issn | 1473-2300 |
| language | English |
| last_indexed | 2024-03-10T11:33:51Z |
| publishDate | 2023-11-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Journal of International Medical Research |
| spelling | doaj.art-9783807094a745c1a1ae4d789606c7bd2023-11-21T19:03:34ZengSAGE PublishingJournal of International Medical Research1473-23002023-11-015110.1177/03000605231212316Safety and efficacy of continuous intravenous labetalol for blood pressure control in neurosurgical patientsRaywat Noiphithak Gahn Duangprasert Sasikan Sukhor Pichayaphong DurongkawerojVich YindeedejObjectives Current evidence supporting the use of continuous intravenous labetalol for blood pressure (BP) control in neurosurgical patients is limited. This study aims to assess the efficacy and safety of labetalol in neurosurgical patients and identify potential contributing factors to these outcomes. Methods We retrospectively reviewed the medical records of neurosurgical patients who received continuous labetalol infusion for BP control. Efficacy was assessed based on the time needed to achieve the target BP (systolic BP ≤ 140 mmHg or diastolic BP ≤ 90 mmHg). Safety was assessed according to adverse events that occurred during labetalol administration. Factors associated with efficacy and safety were analyzed using a logistic regression model. Results Among 79 patients enrolled in this study, 47 (59.49%) achieved the target BP within 1 hour (early response). No factors were significantly associated with an early response. Hypotension was observed in 11 patients (13.9%), and bradycardia was observed in 8 patients (10.1%). Hypotension was significantly associated with patient age and motor impairment, while bradycardia was significantly associated with diabetes mellitus. Conclusion The efficacy and safety profiles of labetalol infusion suggest this treatment as a promising option for BP control in neurosurgical patients.https://doi.org/10.1177/03000605231212316 |
| spellingShingle | Raywat Noiphithak Gahn Duangprasert Sasikan Sukhor Pichayaphong Durongkaweroj Vich Yindeedej Safety and efficacy of continuous intravenous labetalol for blood pressure control in neurosurgical patients Journal of International Medical Research |
| title | Safety and efficacy of continuous intravenous labetalol for blood pressure control in neurosurgical patients |
| title_full | Safety and efficacy of continuous intravenous labetalol for blood pressure control in neurosurgical patients |
| title_fullStr | Safety and efficacy of continuous intravenous labetalol for blood pressure control in neurosurgical patients |
| title_full_unstemmed | Safety and efficacy of continuous intravenous labetalol for blood pressure control in neurosurgical patients |
| title_short | Safety and efficacy of continuous intravenous labetalol for blood pressure control in neurosurgical patients |
| title_sort | safety and efficacy of continuous intravenous labetalol for blood pressure control in neurosurgical patients |
| url | https://doi.org/10.1177/03000605231212316 |
| work_keys_str_mv | AT raywatnoiphithak safetyandefficacyofcontinuousintravenouslabetalolforbloodpressurecontrolinneurosurgicalpatients AT gahnduangprasert safetyandefficacyofcontinuousintravenouslabetalolforbloodpressurecontrolinneurosurgicalpatients AT sasikansukhor safetyandefficacyofcontinuousintravenouslabetalolforbloodpressurecontrolinneurosurgicalpatients AT pichayaphongdurongkaweroj safetyandefficacyofcontinuousintravenouslabetalolforbloodpressurecontrolinneurosurgicalpatients AT vichyindeedej safetyandefficacyofcontinuousintravenouslabetalolforbloodpressurecontrolinneurosurgicalpatients |